Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Paper published in Lancet Psychiatry may help with the accurate detection of this form of autoimmune encephalitis

NMDAR-antibody encephalitis is an autoantibody-mediated disease (a disease caused by a person’s own immune system reacting to proteins in the brain).

Patients typically present with psychiatric features, often before any neurological features appear. This means that sometimes patients can enter and continue down psychiatric pathways and in mental health settings. These settings are not usually optimised for the care of patients with encephalitis. For example, access to lumbar puncture is rare – an essential part of the diagnosis of any encephalitis. This can understandably delay the diagnosis of NMDAR-antibody encephalitis, leading to lags in the initiation of appropriate immune treatments. 

A new study by Al-Diwani et al in Lancet Psychiatry looked at the available world literature of individually-described patients with NMDAR-antibody encephalitis. The authors were able to identify 464 patients who based upon their symptoms and NMDAR-antibody in their spinal fluid were judged to definitely have this condition. They then extracted the changes in their mental state and modelled the extent to which they resembled primary mental illnesses such as schizophrenia, depression and mania.   

The study found that patients with NMDAR-antibody encephalitis presented with a complex co-existing mix of mental state changes, most commonly a combination of mood, psychosis, behavioural, sleep and catatonia which are best described by mixing traditional psychiatric diagnoses. This pattern became more stable when focusing on the cases that had the most detailed descriptions, emphasising the need for professionals to be detailed and clear when describing and reporting mental states.

These observations should encourage the accurate detection of this form of autoimmune encephalitis and differentiate it from other serious mental-health illnesses. In addition, also by contrast to primary psychiatric illnesses, NMDAR-antibody encephalitis often occurs over days and patients typically have seizures and a distinctive movement disorder. Taken together, this set of observations aims to identify this group of immune therapy-sensitive patients from within unselected psychiatric presentations.

The findings of this paper mean:

  • Psychiatrists and other mental health professionals assessing patients with new severe mental health features should have a more nuanced understanding of NMDAR-antibody encephalitis. This may help them to be more confident in who they should consider has NMDAR-antibody encephalitis and who is more likely to not have this illness.
  • This can help guide spinal fluid and blood testing to reduce the need for over-invasive and unnecessary tests and potentially inappropriate immune treatments.
  • It may set the scene for future work to develop clinical triage approaches to speed up the diagnosis of NMDAR-antibody encephalitis.
  • Urgent conversations must be had between neurological and psychiatric communities in order to identify the best way to select and test these NMDAR-antibody encephalitis patients.

Link to BBC News item about this research

Similar stories

Attention and memory deficits persist for months after recovery from mild COVID

Researchers from Oxford’s Nuffield Department of Clinical Neurosciences and Department of Experimental Psychology have shown that people who have had COVID but don’t complain of long COVID symptoms in daily life nevertheless can show degraded attention and memory for up to six to nine months.

New Academic Visitor from Nigeria

Associate Professor of Radiology, Godwin Ogbole has arrived on a six-month visit to the Nuffield Department of Clinical Neurosciences, as part of the Africa Oxford Initiative.

New spinout company: Human-Centric Drug Discovery

Human-Centric Drug Discovery is a new Oxford University spinout company from Professor Zameel Cader's lab.

Funding received for research into Motor Neuron Disease

A £210,000 donation from the Alan Davidson Foundation has been made to our Department to advance our world-leading research into Motor Neuron Disease. The funding will support a project manager to deliver an innovative research project using the genetic causes of MND to develop approaches to early diagnosis.

Research finds drug may benefit some patients hospitalised with COVID-19 pneumonia

A proof-of-concept trial involving Oxford researchers has identified a drug that may benefit some patients hospitalised with COVID-19 pneumonia.

Protein test could lead to earlier and better diagnosis of Parkinson’s

Scientists have observed the clumping of alpha-synuclein in the cerebrospinal fluid taken from people with Parkinson's. The findings offer hope that a pioneering new clinical test could be developed to diagnose Parkinson's correctly in its early stages.